{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012055","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.364175+00:00","generated_at":"2026-05-31T09:55:54.196420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024","bullets":["Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.","Cash and equivalents $26.4M as of June 30, 2024, up from $13.5M at Dec 31, 2023.","Completed enrollment in Phase 2 Tailwind study of inhaled AP-PA02; last patient visit Aug 7, topline data expected H2 2024.","Received $5.25M non-dilutive DoD grant for AP-SA02 diSArm Phase 2a study.","Built out cGMP manufacturing facility with five clean rooms, including fill-and-finish suite."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012055","json":"https://secwatch.observer/filing/0001558370-24-012055.json","markdown":"https://secwatch.observer/filing/0001558370-24-012055.md","text":"https://secwatch.observer/filing/0001558370-24-012055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/0001558370-24-012055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/armp-20240813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:55:54.196420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}